Vitamin K2 and D3 Supplementation in Patients With Severe Coronary Artery Calcification: The DANCODE Trial.

What Was Tested

The paper reports a study of Vitamin D, K2, Magnesium and Zinc, published as a randomized controlled trial.

Coronary artery calcification (CAC) progression is a strong predictor of cardiovascular events.

URL: https://www.clinicaltrials.gov; Unique identifier: NCT05500443.

Who Took Part

The study group was 400 participants.

PubMed indexes the participants as middle-aged adults and older adults, both men and women.

Participants were enrolled from February 2023 to February 2024.

How the Study Was Run

In design terms this was a randomized, double-blind, placebo-controlled and multicenter study.

The participants were allocated by chance, so the Vitamin D, K2, Magnesium and Zinc group and the comparison group should start out alike.

Neither the participants nor the staff measuring them knew who was on Vitamin D, K2, Magnesium and Zinc, so expectations could not easily colour the readings.

A placebo (an inactive look-alike) gave the Vitamin D, K2, Magnesium and Zinc group a baseline to be compared against.

More than one site took part, so the participants came from several places.

Noncontrast cardiac computed tomography was performed at baseline, 12 months, and 24 months.

The primary end point was change in CAC score at 24 months.

Subgroup analyses by sex and baseline CAC subgroups (400-999 and ≥1000 AU) were performed.

Change in plaque composition was assessed in a subset with CAC score <1000 AU who underwent coronary computed tomography angiography at baseline and 24 months.

What Was Measured

The subject headings attached to it are Vitamin K 2, Cholecalciferol, Coronary Artery Disease, Dietary Supplements, Vascular Calcification and Computed Tomography Angiography.

The authors tagged it with the keywords calcification, physiologic, matrix Gla protein, randomized controlled trial, tomography, x-ray computed and x-rays.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Vitamin D, K2, Magnesium and Zinc in 400 participants.

With several hundred people or more, it is a fairly large study for this kind of research.

Its findings take up roughly 7 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2026 (Circulation), a journal based in United States.

More context: the Vitamin D, K2, Magnesium and Zinc compound page, all human trials.